Sun Pharmaceutical Industries Limited has entered into a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at ~$11.75 billion. Under the deal, Sun Pharma will purchase all outstanding shares of Organon at $14 per share.
Organon, formed as a spin-off from Merck (known as MSD outside the United States and Canada) in 2021, is a global healthcare company with a strong focus on women’s health and established medicines.
The company operates in over 140 countries and manages a portfolio of more than 70 products, including biosimilars. Its global footprint is supported by six manufacturing facilities across Europe and emerging markets, ensuring scale and operational efficiency.
The acquisition aligns with Sun Pharma’s long-term strategy of strengthening its innovative medicines business while expanding its branded generics portfolio.
With this deal, Sun Pharma will enter the biosimilars segment as a top-10 global player and significantly enhance its position in women’s healthcare.
Organon’s strong brand equity and global reach are expected to complement Sun Pharma’s existing capabilities and unlock new growth opportunities.
Following the completion of the transaction, the combined entity is expected to rank among the top 25 pharmaceutical companies globally, with combined revenues of ~$12.4 billion.
The company will also emerge as a top-three player in global women’s health and expand its presence to around 150 countries. Additionally, the acquisition is expected to nearly double EBITDA and cash flow, strengthening financial stability and enabling faster deleveraging.
For the year ended December 31, 2025, Organon reported revenues of $6.2 billion and an adjusted EBITDA of $1.9 billion. The company had debt of $8.6 billion and a cash balance of $574 million. Sun Pharma plans to finance the acquisition through a mix of internal cash reserves and committed bank financing.
The transaction has received board approvals from both companies and is subject to regulatory clearances and shareholder approval, with closure expected in early 2027.
On April 27, 2026, Sun Pharma share price opened at ₹1,625.00. At 12:13 PM, the share price of Sun Pharma was trading at ₹1,731.30, up by 6.84% on the NSE.
Also Read: Sun Pharma Share Price Fall 5% Despite Strong Market: Key Reasons Behind the Decline!
The acquisition of Organon represents a transformative step for Sun Pharma, enhancing its global scale, diversifying its portfolio, and strengthening its presence in high-growth segments like women’s health and biosimilars. If executed successfully, the deal is poised to drive long-term value creation and solidify Sun Pharma’s position as a leading global pharmaceutical player.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 27, 2026, 12:42 PM IST
Nikitha Devi
Nikitha is a content creator with 7+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
